About this Research Topic
In the last decade, significant advances in understanding the pathophysiology of skin diseases have led to the development of new drugs and medical devices. Biologics, small molecule inhibitors, and enzymes have revolutionized the prevention and treatment of chronic inflammatory disorders (i.e. atopic dermatitis, psoriasis) and rare inherited skin diseases (i.e. Xeroderma pigmentosum).
Biologics [i.e. Dupilumab, secukinumab] target cytokines and receptors: small molecule inhibitors [i.e. Phosphodiesterase 4 (PDE) Inhibitor, Deucravacitinib] interact with intracellular signaling molecules: and enzyme therapies (i.e. photolyase and T4 endonuclease V) replace enzymes that are deficient or absent in the body. Given the numerous therapeutics currently under investigation, the collection of the latest research would be a useful tool for the re-evaluation of their efficacy and side effects.
The Research Topic welcomes original research articles and relevant topic reviews covering recent advances in skin precision medicine including, but not limited to, the following topics:
• Immunotherapy: the latest developments in immunotherapeutic approaches for treating skin diseases, including novel biologics targeting immune cells or cytokines involved in inflammatory pathways.
• Gene Editing Techniques: the application of CRISPR/Cas9 and other gene editing technologies in correcting genetic mutations underlying inherited skin disorders.
• DNA Repair Mechanisms: the role of DNA repair pathways in maintaining skin homeostasis and their dysregulation in diseases like skin cancer.
• Innovative Drug Delivery Systems: the use of drug delivery systems such as nanoparticles, microneedles, or liposomal formulations, designed to improve the localized delivery and efficacy of dermatological therapeutics while minimizing systemic toxicity and side effects.
• Enzyme Replacement Therapies: the role and effectiveness of enzyme therapies in addressing deficiencies associated with rare inherited skin disorders.
Biologics [i.e. Dupilumab, secukinumab] target cytokines and receptors: small molecule inhibitors [i.e. Phosphodiesterase 4 (PDE) Inhibitor, Deucravacitinib] interact with intracellular signaling molecules: and enzyme therapies (i.e. photolyase and T4 endonuclease V) replace enzymes that are deficient or absent in the body. Given the numerous therapeutics currently under investigation, the collection of the latest research would be a useful tool for the re-evaluation of their efficacy and side effects.
The Research Topic welcomes original research articles and relevant topic reviews covering recent advances in skin precision medicine including, but not limited to, the following topics:
• Immunotherapy: the latest developments in immunotherapeutic approaches for treating skin diseases, including novel biologics targeting immune cells or cytokines involved in inflammatory pathways.
• Gene Editing Techniques: the application of CRISPR/Cas9 and other gene editing technologies in correcting genetic mutations underlying inherited skin disorders.
• DNA Repair Mechanisms: the role of DNA repair pathways in maintaining skin homeostasis and their dysregulation in diseases like skin cancer.
• Innovative Drug Delivery Systems: the use of drug delivery systems such as nanoparticles, microneedles, or liposomal formulations, designed to improve the localized delivery and efficacy of dermatological therapeutics while minimizing systemic toxicity and side effects.
• Enzyme Replacement Therapies: the role and effectiveness of enzyme therapies in addressing deficiencies associated with rare inherited skin disorders.
Keywords: skin disease, biologics, enzymes, precision medicine, immunotherapy
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
